Analysis: Takeda Buy Of Amgen Subsidiary Could Trigger Sell Off Of Japanese Units
This article was originally published in PharmAsia News
Takeda's acquisition of U.S. biotech Amgen's Japanese subsidiary could signal a shift of foreign drug maker focus from maintaining subsidiaries in Japan to selling them so they can focus instead on China and India. An official at a major Japanese pharmaceutical said many of the world's biggest drug makers are considering selling their units in Japan. Several years ago, the same drug makers were emphasizing expansions into Japan, then the world's second-largest drug market. The companies have since learned Japan has a lengthy and costly process of clinical trials. (Click here for more - a subscription may be required
You may also be interested in...
The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.